Elizabeth Harmon Stover, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 11 | 2024 | 4904 | 0.930 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 7 | 2006 | 102 | 0.780 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 7 | 2006 | 367 | 0.690 |
Why?
|
| bcl-X Protein | 1 | 2019 | 412 | 0.580 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2020 | 5334 | 0.470 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2019 | 1150 | 0.450 |
Why?
|
| BRCA1 Protein | 4 | 2023 | 1155 | 0.370 |
Why?
|
| Genetic Testing | 2 | 2020 | 3592 | 0.350 |
Why?
|
| BRCA2 Protein | 3 | 2023 | 802 | 0.310 |
Why?
|
| Gene Amplification | 2 | 2025 | 1088 | 0.300 |
Why?
|
| DNA Repair | 1 | 2016 | 2048 | 0.280 |
Why?
|
| Hypereosinophilic Syndrome | 5 | 2006 | 97 | 0.280 |
Why?
|
| Endometrial Neoplasms | 3 | 2023 | 1379 | 0.260 |
Why?
|
| DNA Replication | 3 | 2021 | 1426 | 0.250 |
Why?
|
| Isoxazoles | 2 | 2024 | 233 | 0.240 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2006 | 1609 | 0.230 |
Why?
|
| Apoptosis | 1 | 2019 | 9507 | 0.210 |
Why?
|
| RNA, Satellite | 1 | 2022 | 16 | 0.200 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 9378 | 0.200 |
Why?
|
| Credentialing | 1 | 2022 | 113 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 2897 | 0.190 |
Why?
|
| Pyrimidines | 5 | 2006 | 3048 | 0.180 |
Why?
|
| Pyrazines | 2 | 2024 | 1204 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 5695 | 0.180 |
Why?
|
| Deoxycytidine | 2 | 2024 | 886 | 0.180 |
Why?
|
| Cystadenoma, Serous | 1 | 2020 | 99 | 0.170 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 13634 | 0.170 |
Why?
|
| Mutation | 12 | 2022 | 30208 | 0.160 |
Why?
|
| Ovary | 2 | 2020 | 961 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 11092 | 0.160 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 2535 | 0.150 |
Why?
|
| Ascites | 1 | 2020 | 336 | 0.150 |
Why?
|
| Neoplasms | 4 | 2025 | 22336 | 0.150 |
Why?
|
| Ovariectomy | 1 | 2020 | 612 | 0.150 |
Why?
|
| Cell Membrane | 1 | 2006 | 3635 | 0.130 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 17070 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 432 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 877 | 0.130 |
Why?
|
| Paclitaxel | 2 | 2022 | 1725 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3546 | 0.120 |
Why?
|
| DNA Polymerase II | 1 | 2015 | 103 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2025 | 8613 | 0.120 |
Why?
|
| Genomics | 3 | 2020 | 5924 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 3664 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2020 | 2226 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.110 |
Why?
|
| Piperazines | 5 | 2018 | 2547 | 0.110 |
Why?
|
| Cisplatin | 1 | 2019 | 1654 | 0.110 |
Why?
|
| Actins | 1 | 2020 | 2060 | 0.110 |
Why?
|
| Immunity | 1 | 2018 | 1001 | 0.100 |
Why?
|
| Cell Line | 3 | 2022 | 15545 | 0.100 |
Why?
|
| Microsatellite Instability | 1 | 2015 | 726 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 11858 | 0.100 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 1425 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3594 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2020 | 2864 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 1105 | 0.080 |
Why?
|
| DNA Copy Number Variations | 3 | 2025 | 2043 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 3 | 2006 | 2729 | 0.080 |
Why?
|
| Carcinoma | 2 | 2019 | 2313 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 11202 | 0.080 |
Why?
|
| Humans | 32 | 2025 | 766000 | 0.080 |
Why?
|
| Patient Selection | 1 | 2020 | 4249 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 2 | 2005 | 615 | 0.070 |
Why?
|
| Female | 20 | 2025 | 396158 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 6840 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 170 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2007 | 298 | 0.060 |
Why?
|
| Dimerization | 1 | 2006 | 881 | 0.060 |
Why?
|
| Hedgehog Proteins | 1 | 2009 | 771 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2007 | 552 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2007 | 376 | 0.060 |
Why?
|
| Pantoea | 1 | 2003 | 14 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 614 | 0.050 |
Why?
|
| Regulon | 1 | 2003 | 71 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 9237 | 0.050 |
Why?
|
| Mastocytosis, Systemic | 1 | 2004 | 102 | 0.050 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 84 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 2038 | 0.050 |
Why?
|
| Staurosporine | 1 | 2003 | 240 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2018 | 7850 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2025 | 818 | 0.050 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.050 |
Why?
|
| Point Mutation | 1 | 2006 | 1591 | 0.040 |
Why?
|
| Neuroendocrine Tumors | 1 | 2007 | 657 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2020 | 108 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2020 | 191 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2009 | 2060 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2020 | 189 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 14065 | 0.040 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
| Germ Cells | 1 | 2023 | 646 | 0.040 |
Why?
|
| Oncogenes | 2 | 2021 | 1231 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 310 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 3750 | 0.040 |
Why?
|
| Survival Rate | 2 | 2020 | 12821 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2002 | 702 | 0.040 |
Why?
|
| Computational Biology | 2 | 2021 | 3563 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 167 | 0.040 |
Why?
|
| Benzamides | 4 | 2006 | 1376 | 0.040 |
Why?
|
| Online Systems | 1 | 2019 | 181 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 1525 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2003 | 1384 | 0.040 |
Why?
|
| Leukemia | 1 | 2006 | 1521 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 21072 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 752 | 0.040 |
Why?
|
| Mice | 7 | 2020 | 81821 | 0.030 |
Why?
|
| Animals | 9 | 2021 | 168775 | 0.030 |
Why?
|
| Workflow | 1 | 2021 | 859 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 3405 | 0.030 |
Why?
|
| RNA | 2 | 2022 | 2715 | 0.030 |
Why?
|
| Phthalazines | 1 | 2018 | 397 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2025 | 1883 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 3722 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 2227 | 0.030 |
Why?
|
| DNA Damage | 1 | 2025 | 2464 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2021 | 1273 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 1189 | 0.030 |
Why?
|
| Pyridines | 1 | 2006 | 2889 | 0.030 |
Why?
|
| Astrocytes | 1 | 2002 | 1353 | 0.030 |
Why?
|
| Protein Binding | 1 | 2006 | 9302 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 2425 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 3610 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2020 | 23600 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2006 | 378 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2006 | 18964 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2611 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6101 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10736 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 1801 | 0.020 |
Why?
|
| Neoplasms, Experimental | 2 | 2009 | 1227 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2006 | 1494 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 2210 | 0.020 |
Why?
|
| Retroviridae | 2 | 2003 | 845 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2017 | 1755 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2020 | 4161 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 3831 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4262 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3942 | 0.020 |
Why?
|
| Stem Cells | 1 | 2002 | 3537 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 29904 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 18314 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6506 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1885 | 0.020 |
Why?
|
| Aged | 5 | 2021 | 171161 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 1996 | 0.020 |
Why?
|
| Phenotype | 2 | 2022 | 16712 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2018 | 2747 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2009 | 221 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 11035 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 13482 | 0.020 |
Why?
|
| Male | 4 | 2022 | 363855 | 0.020 |
Why?
|
| Adult | 6 | 2021 | 223106 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2004 | 17597 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 4779 | 0.020 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2007 | 241 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2003 | 5019 | 0.020 |
Why?
|
| Centromere | 1 | 2006 | 214 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14455 | 0.010 |
Why?
|
| Herpes Zoster | 1 | 2007 | 252 | 0.010 |
Why?
|
| K562 Cells | 1 | 2006 | 644 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 11642 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9524 | 0.010 |
Why?
|
| Niacinamide | 1 | 2006 | 419 | 0.010 |
Why?
|
| Middle Aged | 5 | 2021 | 223025 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2004 | 216 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13613 | 0.010 |
Why?
|
| Introns | 1 | 2006 | 965 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 744 | 0.010 |
Why?
|
| Phenylurea Compounds | 1 | 2006 | 536 | 0.010 |
Why?
|
| Neurons | 1 | 2002 | 9520 | 0.010 |
Why?
|
| Time Factors | 2 | 2020 | 40100 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 812 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 2003 | 240 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 65199 | 0.010 |
Why?
|
| Sigma Factor | 1 | 2003 | 177 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2002 | 194 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 13400 | 0.010 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 1245 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 158 | 0.010 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2003 | 429 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 1331 | 0.010 |
Why?
|
| Epistasis, Genetic | 1 | 2003 | 353 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 837 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2003 | 575 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 1739 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 22334 | 0.010 |
Why?
|
| Multigene Family | 1 | 2003 | 1081 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2003 | 1159 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 2510 | 0.010 |
Why?
|
| Telomere | 1 | 2006 | 941 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6361 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 839 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1695 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2003 | 1865 | 0.010 |
Why?
|
| Homozygote | 1 | 2002 | 1775 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 2413 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2003 | 1592 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 2294 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 6961 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2003 | 1137 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2002 | 2625 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41675 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 2062 | 0.010 |
Why?
|
| Risk Factors | 1 | 2023 | 74838 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2004 | 3605 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 3733 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 2838 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3399 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2009 | 3636 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 3448 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2003 | 2916 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54797 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 7192 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 12405 | 0.010 |
Why?
|
| Child | 1 | 2020 | 80567 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 2945 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 9351 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2003 | 4209 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 8494 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 59493 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10431 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 81542 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 4282 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 21509 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 9600 | 0.000 |
Why?
|
| Transcription Factors | 1 | 2003 | 12128 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 36545 | 0.000 |
Why?
|